|
WO9956776A2
|
|
Adjuvant composition and methods for its use
|
|
US6013640A
|
|
Phosphoglycolipid and methods for its use
|
|
US6113918A
|
|
Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
|
|
US5762943A
|
|
Methods of treating type I hypersensitivity using monophosphoryl lipid A
|
|
CA2127037A1
|
|
Method and composition for ameliorating tissue damage due to ischemia and reperfusion
|
|
US5286718A
|
|
Method and composition for ameliorating tissue damage due to ischemia and reperfusion
|
|
US4912094A
|
|
Modified lipopolysaccharides and process of preparation
|
|
US4987237A
|
|
Derivatives of monophosphoryl lipid A
|
|
US4877611A
|
|
Vaccine containing tumor antigens and adjuvants
|
|
ES2005167A6
|
|
Immunological adjuvant enhancing immune response to vaccine antigens
|
|
US4844894A
|
|
Method of inhibiting the onset of septicemia and endotoxemia
|
|
US4803070A
|
|
Immunological emulsion adjuvants for polysaccharide vaccines
|
|
US4806352A
|
|
Immunological lipid emulsion adjuvant
|
|
US4866034A
|
|
Refined detoxified endotoxin
|
|
US4613504A
|
|
Pyridine-soluble extracts of microorganisms
|
|
CA1225592A
|
|
Refined detoxified endotoxin
|
|
US4503048A
|
|
Pyridine soluble extract of a microorganism
|
|
US4629722A
|
|
Method of inhibiting the onset of acute radiation syndrome
|
|
US4504473A
|
|
Pyridine soluble extract of a microorganism
|
|
US4505903A
|
|
Pyridine soluble extract of a microorganism
|
